Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Vertex Ventures HC
AddedFeb 13, 2024
UpdatedJun 28, 2026
Vertex Ventures HC

Vertex Ventures HC

Operating

Vertex Ventures HC: A global healthcare investment firm specializing in biopharma, medical devices, and digital health.

Location
San Francisco, CA, US
Founded
2014
Firm
Compare
Portfolio
Employees
Website

Investments

SonoThera
SonoThera
Series B

Total Raised

$185.8M

Rounds

2

Series B$125MJune 2026
Series A$60.8MDecember 2022
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Spyglass Pharma
Spyglass Pharma

Total Raised

$109.8M

Rounds

3

Series C$90MJuly 2023
Boundless Bio
Boundless Bio

Total Raised

$251.4M

Rounds

3

Series C$100MMay 2023
Series B$105MApril 2021
Torl Biotherapeutics
Torl Biotherapeutics

Total Raised

$158M

Rounds

1

Series B$158MApril 2023
Matchpoint Therapeutics
Matchpoint Therapeutics

Total Raised

$100M

Rounds

2

Series A$70MOctober 2022
Allay Therapeutics
Allay Therapeutics

Total Raised

$118.9M

Rounds

4

Series C$86.9MSeptember 2021
Obsidian Therapeutics
Obsidian Therapeutics

Total Raised

$164.5M

Rounds

2

Series B$115MSeptember 2021
Series A$49.5MDecember 2017
Sonoma Biotherapeutics
Sonoma Biotherapeutics

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Neuspera Medical
Neuspera Medical

Total Raised

$111.9M

Rounds

4

Series C$65MJuly 2021
Palleon Pharmaceuticals
Palleon Pharmaceuticals

Total Raised

$147.6M

Rounds

2

Series B$100MSeptember 2020
Series A$47.6MOctober 2017
Epirium Bio
Epirium Bio

Total Raised

$86.4M

Rounds

3

Series A$85MDecember 2019
BlackThorn Therapeutics
BlackThorn Therapeutics
Acquired

Total Raised

$138M

Rounds

4

Series B$76MJune 2019
Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics

Total Raised

$80M

Rounds

3

Series A$15MMay 2019
Series A$65MSeptember 2018
Nuvaira
Nuvaira

Total Raised

$204M

Rounds

10

Series E$79MFebruary 2019
Series D$42MApril 2014
Earlens
Earlens

Total Raised

$318.8M

Rounds

9

Series D$87MOctober 2018
Series C$73MJune 2017
Series C$34MJune 2016
Moximed
Moximed
Public

Total Raised

$183.2M

Rounds

8

Series B$33MMay 2015